A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).

Authors

Kedar Kirtane

Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL

Kedar Kirtane , Ines Verdon , Maclean Hall , Shari Pilon-Thomas , Jobelle Joyce Anne Baldonado , Guilherme Rabinowits , Christine H. Chung

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.

First Author: Daniel Olson

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.

First Author: Paolo Antonio Ascierto

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

First Author: Sajeve Samuel Thomas

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

First Author: Arlene O. Siefker-Radtke